Last reviewed · How we verify

Tozinameran 6 months to 4 years of age — Competitive Intelligence Brief

Tozinameran 6 months to 4 years of age (tozinameran-6-months-to-4-years-of-age) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine SARS-CoV-2 spike protein Immunology Live · refreshed every 30 min

Target snapshot

Tozinameran 6 months to 4 years of age (tozinameran-6-months-to-4-years-of-age) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tozinameran 6 months to 4 years of age TARGET tozinameran-6-months-to-4-years-of-age Pfizer marketed vaccine SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age famtozinameran-5-to-11-years-of-age Pfizer marketed Monoclonal antibody SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1) bnt162b2-bivalent-wt-omi-ba-1 Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein
Comirnaty Original/Omicron BA.4-5 Comirnaty Original/Omicron BA.4-5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
Combination BNT162b2 and BNT162b2 OMI combination-bnt162b2-and-bnt162b2-omi Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5) bnt162b7-monovalent-omi-ba-4-ba-5 Pfizer marketed vaccine SARS-CoV-2 spike protein
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

  1. Pfizer · 20 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
  3. GlaxoSmithKline · 12 drugs in this class
  4. Merck Sharp & Dohme LLC · 12 drugs in this class
  5. Centers for Disease Control and Prevention · 9 drugs in this class
  6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
  7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
  8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
  9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
  10. Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tozinameran 6 months to 4 years of age — Competitive Intelligence Brief. https://druglandscape.com/ci/tozinameran-6-months-to-4-years-of-age. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: